Jazz Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JAZZ and other ETFs, options, and stocks.

About JAZZ

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. 

CEO
Renée D. Galá
CEORenée D. Galá
Employees
2,890
Employees2,890
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2005
Founded2005
Employees
2,890
Employees2,890

JAZZ Key Statistics

Market cap
16.02B
Market cap16.02B
Price-Earnings ratio
17.02
Price-Earnings ratio17.02
Dividend yield
Dividend yield
Average volume
1.46M
Average volume1.46M
High today
$248.97
High today$248.97
Low today
$244.75
Low today$244.75
Open price
$246.00
Open price$246.00
Volume
321.65K
Volume321.65K
52 Week high
$266.38
52 Week high$266.38
52 Week low
$123.88
52 Week low$123.88

Stock Snapshot

As of today, Jazz Pharmaceuticals(JAZZ) shares are valued at $246.81. The company's market cap stands at 16.02B, with a P/E ratio of 17.02.

During the trading session on 2026-09-06, Jazz Pharmaceuticals(JAZZ) shares reached a daily high of $248.97 and a low of $244.75. At a current price of $246.81, the stock is +0.8% higher than the low and still -0.9% under the high.

Trading volume for Jazz Pharmaceuticals(JAZZ) stock has reached 321.65K, versus its average volume of 1.46M.

The stock's 52-week range extends from a low of $123.88 to a high of $266.38.

The stock's 52-week range extends from a low of $123.88 to a high of $266.38.

JAZZ News

Simply Wall St 4d
Why Jazz Pharmaceuticals Is Down 6.3% After Ziihera’s First-Line HER2-Positive GEA Survival Data And What's Next

In late August 2026, Jazz Pharmaceuticals reported second interim Phase 3 HERIZON-GEA-01 data and confirmed prior US FDA approvals showing that Ziihera (zanidat...

Why Jazz Pharmaceuticals Is Down 6.3% After Ziihera’s First-Line HER2-Positive GEA Survival Data And What's Next
TipRanks 6d
Jazz Pharmaceuticals Completes $1.25 Billion Notes Offering

Jazz Pharmaceuticals ( (JAZZ) ) just unveiled an announcement. On August 31, 2026, Jazz Investments I Limited, a wholly owned subsidiary of Jazz Pharmaceutical...

Simply Wall St 7d
Jazz Pharmaceuticals Could Be 13% Undervalued On FDA Approval Of Ziihera

Jazz Pharmaceuticals (JAZZ) is in focus after the FDA approved Ziihera-based regimens for first-line treatment of adults with unresectable locally advanced or m...

Jazz Pharmaceuticals Could Be 13% Undervalued On FDA Approval Of Ziihera

Analyst ratings

86%

of 22 ratings
Buy
86.4%
Hold
13.6%
Sell
0%

People also own

Based on the portfolios of people who own JAZZ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.